oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2024-23-2-101-110oncotomsk-3047Research ArticleОБЗОРЫREVIEWSАссоциация медиаторов жировой ткани с развитием злокачественных новообразований на фоне метаболического синдромаAssociation of adipose tissue mediators with the development of cancer in patients with metabolic syndromehttps://orcid.org/0000-0002-7752-9346СередаЕ. Е.SeredaE. E.

Середа Елена Евгеньевна - доктор медицинских наук, старший научный сотрудник лаборатории биохимии опухолей, Научно-исследовательский институт онкологии, Томский НИМЦ РАН; доцент кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «СибГМУ» Минздрава России.

634009, Томск, пер. Кооперативный, 5; 634050, Томск, Московский тракт, 2

Researcher ID (WOS): D-1472-2012; Author ID (Scopus): 54994115800

Elena E. Sereda - MD, DSc, Senior Researcher, Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Associate Professor, Department of Biochemistry and Molecular Biology with Clinical Laboratory Diagnostics, Siberian State Medical University of the Ministry of Health of Russia.

5, Kooperativny St., Tomsk, 634009; 2, Moskovsky Trakt, Tomsk, 634050

Researcher ID (WOS): D-1472-2012; Author ID (Scopus): 54994115800

shashova7ssmu@gmail.comhttps://orcid.org/0000-0002-8194-2811ЧернышоваА. Л.ChernyshovaA. L.

Чернышова Алена Леонидовна - доктор медицинских наук, профессор РАН, главный научный сотрудник отделения гинекологии.

634009, Томск, пер. Кооперативный, 5

Researcher ID (WOS): C-8608-2012; Author ID (Scopus): 55220758100

Alena L. Chernyshova - MD, DSc, Professor, Chief Researcher, Department of Gynecological Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS): C-8608-2012; Author ID (Scopus): 55220758100

МамоноваТ. Ю.MamonovaT. Yu.

Мамонова Татьяна Юрьевна - кандидат медицинских наук, врач-терапевт.

634009, Томск, пер. Кооперативный, 5

Tatiana Yu. Mamonova - MD, PhD, Therapist, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

https://orcid.org/0000-0002-4506-9429КакуринаГ. В.KakurinaG. V.

Какурина Гелена Валерьевна - кандидат медицинских наук, старший научный сотрудник лаборатории биохимии опухолей, Научно-исследовательский институт онкологии, Томский НИМЦ РАН; доцент кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «СибГМУ» Минздрава России.

634009, Томск, пер. Кооперативный, 5; 634050, Томск, Московский тракт, 2

Researcher ID (WOS): C-8668-2012; Author ID (Scopus): 23667534500

Gelena V. Kakurina - MD, PhD, Senior Researcher, Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Associate Professor, Department of Biochemistry and Molecular Biology with a Course in Clinical Laboratory Diagnostics, Siberian State Medical University of the Ministry of Health of Russia.

5, Kooperativny St., Tomsk, 634009; 2, Moskovsky Trakt, Tomsk, 634050

Researcher ID (WOS): C-8668-2012; Author ID (Scopus): 23667534500

https://orcid.org/0000-0003-4595-4177ЮнусоваН. В.YunusovaN. V.

Юнусова Наталья Валерьевна - доктор медицинских наук, главный научный сотрудник лаборатории биохимии опухолей, НИИ онкологии, Томский НИМЦ РАН; профессор кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «СибГМУ» Минздрава России.

634009, Томск, пер. Кооперативный, 5; 634050, Томск, Московский тракт, 2

Researcher ID (WOS): C-9275-2012; Author ID (Scopus): 8354141400

Natalia V. Yunusova - MD, DSc, Chief Researcher, Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Professor, Department of Biochemistry and Molecular Biology with Clinical Laboratory Diagnostics, Siberian State Medical University of the Ministry of Health of Russia.

5, Kooperativny St., Tomsk, 634009; 2, Moskovsky Trakt, Tomsk, 634050

Researcher ID (WOS): C-9275-2012; Author ID (Scopus): 8354141400

https://orcid.org/0000-0001-5838-9459СиденкоЕ. А.SidenkoE. A.

Сиденко Евгения Александровна - кандидат медицинских наук, младший научный сотрудник лаборатории биохимии опухолей, НИИ онкологии, Томский НИМЦ РАН; ассистент кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «СибГМУ» Минздрава России.

634009, Томск, пер. Кооперативный, 5; 634050, Томск, Московский тракт, 2

Researcher ID (WOS): AAG-1291-2021; Author ID (Scopus): 57216126104

Evgenia A. Sidenko - MD, PhD, Junior Researcher, Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Assistant, Department of Biochemistry and Molecular Biology with a Course of Clinical Laboratory Diagnostics, Siberian State Medical University of the Ministry of Health of Russia.

5, Kooperativny St., Tomsk, 634009; 2, Moskovsky Trakt, Tomsk, 634050

Researcher ID (WOS): AAG-1291-2021; Author ID (Scopus): 57216126104

https://orcid.org/0000-0002-1058-3882КоршуновД. А.KorshunovD. A.

Коршунов Дмитрий Афанасьевич - кандидат медицинских наук, научный сотрудник лаборатории биохимии опухолей.

634009, Томск, пер. Кооперативный, 5

Researcher ID (WOS): C-9900-2017; Author ID (Scopus): 37037590600

Dmitry A. Korshunov - MD, PhD, Research, Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS): C-9900-2017; Author ID (Scopus): 37037590600

https://orcid.org/0000-0002-0947-8778КондаковаИ. В.KondakovaI. V.

Кондакова Ирина Викторовна - доктор медицинских наук, профессор, заведующая лабораторией биохимии опухолей.

634009, Томск, пер. Кооперативный, 5

Researcher ID (WOS): C-8658-2012; Author ID (Scopus): 6701872510

Irina V. Kondakova - MD, DSc, Professor, Head of the Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

5, Kooperativny St., Tomsk, 634009

Researcher ID (WOS): C-8658-2012; Author ID (Scopus): 6701872510

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of The Ministry of Health of RussiaRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation202412052024232101110Copyright © Середа Е.Е., Чернышова А.Л., Мамонова Т.Ю., Какурина Г.В., Юнусова Н.В., Сиденко Е.А., Коршунов Д.А., Кондакова И.В., 20242024Середа Е.Е., Чернышова А.Л., Мамонова Т.Ю., Какурина Г.В., Юнусова Н.В., Сиденко Е.А., Коршунов Д.А., Кондакова И.В.Sereda E.E., Chernyshova A.L., Mamonova T.Y., Kakurina G.V., Yunusova N.V., Sidenko E.A., Korshunov D.A., Kondakova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/3047

Цель исследования – обобщение имеющихся данных о взаимосвязи медиаторов жировой ткани с течением злокачественных новообразований у больных с метаболическим синдромом. Материал и методы. Используя электронные ресурсы поисковых систем PubMed и eliBRARY, проведен литературный обзор научных трудов за последние 20 лет, содержащих доказательную экспериментальную и клиническую базу по обсуждаемым вопросам. Из 400 найденных по ключевым словам публикаций в обзор включено 58 исследований. Результаты. Имеются данные о неблагоприятном течении онкологических заболеваний у больных с метаболическим синдромом, что обусловлено наличием общих патогенетических путей. В обзоре особое внимание уделено медиаторам жировой ткани, регулирующим течение воспаления, и обсуждается их вовлечение в патогенез рака. Рассмотрена связь адипокинов жировой ткани и эффектов специализированных проразрешающих медиаторов (СпРМ), которые являются метаболитами полиненасыщенных жирных кислот (резольвины, протектины и марезины). Освещены ассоциации медиаторов, регулирующих интенсивность воспаления, с метаболическим синдромом и злокачественными новообразованиями. Заключение. Более подробное изучение данного вопроса будет способствовать пониманию патогенеза злокачественных новообразований при метаболическом синдроме и поиску адекватных предиктивных маркеров для выбора наиболее эффективной медикаментозной стратегии коррекции метаболического синдрома, которую можно было бы применить у пациентов с онкологической патологией.

The aim of the study was to summarize the available data on the relationship between adipose tissue mediators and cancer in patients with metabolic syndrome. Material and methods. A literature search was conducted using the PubMed and eliBRARY databases. Of the 400 articles published over the past 20 years, 58 studies were included in the review. Results. There is evidence of an unfavorable course of cancer in patients with metabolic syndrome that is explained by the presence of common pathogenetic pathways. In this review, special attention is paid to adipose tissue mediators that regulate the course of inflammation. The involvement of adipose tissue mediators in the pathogenesis of cancer is discussed. The relationship between adipokines of adipose tissue and the effects of specialized pro-resolving mediators (SpRM), which are metabolites of polyunsaturated fatty acids (resolvins, protectins and maresins), are considered. the associations of mediators that regulate the intensity of inflammation with the metabolic syndrome and cancer are discussed. Conclusion. Further studies will contribute to a better understanding of the relationship between metabolic syndrome and cancer and the search for adequate predictive markers to select the most effective drug strategy for correcting metabolic syndrome.

злокачественные новообразованияметаболический синдромадипокиныспециализированные проразрешающие медиаторы (СпРМ)метаболиты полиненасыщенных жирных кислотcancermetabolic syndromeadipokinesspecialized pro-resolving mediators (SpRMs)metabolites of polyunsaturated fatty acidsReferencesMili N., Paschou S.A., Goulis D.G., Dimopoulos M.A., Lambrinoudaki I., Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74(3):478–97. doi: 10.1007/s12020-021-02884-x.Mili N., Paschou S.A., Goulis D.G., Dimopoulos M.A., Lambrinoudaki I., Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74(3):478–97. doi: 10.1007/s12020-021-02884-x.Рекомендации по ведению больных с метаболическим синдромом, разработанные по поручению Минздрава России и утвержденные Российским медицинским обществом по артериальной гипертонии и профильной комиссией по кардиологии. М., 2013.Recommendations for the management of patients with metabolic syndrome developed on behalf of the Russian Ministry of Health and approved by the Russian Medical Society forArterial Hypertension and the Specialized Commission on Cardiology. Moscow, 2013. (in Russian).Чернышова А.Л., Коломиец Л.А., Юнусова Н.В., Шаншашвили Е.В. Особенности гормонально-энергетического обмена у больных с гиперпластическими процессами и раком эндометрия на фоне метаболического синдрома. Сибирский онкологический журнал. 2015;1(1): 5–12.Chernyshova A.L., Kolomiets L.A., Yunusova N.V., Shanshashvili Е.V. Hormonal and energetic changes in patients with endometrial hyperplasia and endometrial cancer. Siberian Journal of Oncology. 2015;1(1): 5–12. (in Russian).Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Kishkina A.Y., Spirina L.V. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr. 2018; 12(5): 807–12. doi: 10.1016/j.dsx.2018.04.028.Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Kishkina A.Y., Spirina L.V. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr. 2018; 12(5): 807–12. doi: 10.1016/j.dsx.2018.04.028.Conteduca V., Caffo O., Galli L., Maugeri A., Scarpi E., Maines F., Chiuri V.E., Lolli C., Kinspergher S., Schepisi G., Santoni M., Santini D., Fratino L., Burgio S.L., Salvi S., Menna C., De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 2018; 36(5). doi: 10.1016/j.urolonc.2018.01.007.Conteduca V., Caffo O., Galli L., Maugeri A., Scarpi E., Maines F., Chiuri V.E., Lolli C., Kinspergher S., Schepisi G., Santoni M., Santini D., Fratino L., Burgio S.L., Salvi S., Menna C., De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 2018; 36(5). doi: 10.1016/j.urolonc.2018.01.007.Kokts-Porietis R.L., McNeil J., Nelson G., Courneya K.S., Cook L.S., Friedenreich C.M. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020; 158(3): 727–33. doi: 10.1016/j.ygyno.2020.06.488.Kokts-Porietis R.L., McNeil J., Nelson G., Courneya K.S., Cook L.S., Friedenreich C.M. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020; 158(3): 727–33. doi: 10.1016/j.ygyno.2020.06.488.Yang X., Li X., Dong Y., Fan Y., Cheng Y., Zhai L., Zhang S., Zhou J., Wang J. Effects of Metabolic Syndrome and Its Components on the Prognosis of Endometrial Cancer. Front Endocrinol (Lausanne). 2021; 12. doi: 10.3389/fendo.2021.780769.Yang X., Li X., Dong Y., Fan Y., Cheng Y., Zhai L., Zhang S., Zhou J., Wang J. Effects of Metabolic Syndrome and Its Components on the Prognosis of Endometrial Cancer. Front Endocrinol (Lausanne). 2021; 12. doi: 10.3389/fendo.2021.780769.Buono G., Crispo A., Giuliano M., De Angelis C., Schettini F., Forestieri V., Lauria R., De Laurentiis M., De Placido P., Rea C.G., Pacilio C., Esposito E., Grimaldi M., Nocerino F., Porciello G., Giudice A., Amore A., Minopoli A., Botti G., De Placido S., Trivedi M.V., Arpino G. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020; 182(2):401–9. doi: 10.1007/s10549-020-05701-7.Buono G., Crispo A., Giuliano M., De Angelis C., Schettini F., Forestieri V., Lauria R., De Laurentiis M., De Placido P., Rea C.G., Pacilio C., Esposito E., Grimaldi M., Nocerino F., Porciello G., Giudice A., Amore A., Minopoli A., Botti G., De Placido S., Trivedi M.V., Arpino G. Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020; 182(2):401–9. doi: 10.1007/s10549-020-05701-7.Li Y., Zhao J., Wu X., Zhang Y., Jin Y., Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY). 2021; 13(4): 5442–60. doi: 10.18632/aging.202474.Li Y., Zhao J., Wu X., Zhang Y., Jin Y., Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY). 2021; 13(4): 5442–60. doi: 10.18632/aging.202474.Bhome R., Peppa N., Karar S., McDonnell D., Mirnezami A., Hamady Z. Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients. Eur J Surg Oncol. 2021; 47(7): 1623–8. doi: 10.1016/j.ejso.2020.12.016.Bhome R., Peppa N., Karar S., McDonnell D., Mirnezami A., Hamady Z. Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients. Eur J Surg Oncol. 2021; 47(7): 1623–8. doi: 10.1016/j.ejso.2020.12.016.Han F., Wu G., Zhang S., Zhang J., Zhao Y., Xu J. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: a systematic review and meta-analysis. Int J Biol Sci. 2021; 17(2): 487–97. doi: 10.7150/ijbs.52452.Han F., Wu G., Zhang S., Zhang J., Zhao Y., Xu J. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: a systematic review and meta-analysis. Int J Biol Sci. 2021; 17(2): 487–97. doi: 10.7150/ijbs.52452.Zhou J., Massey S., Story D., Li L. Metformin: An Old Drug with New Applications. Int J Mol Sci. 2018; 19(10): 2863. doi: 10.3390/ijms19102863.Zhou J., Massey S., Story D., Li L. Metformin: An Old Drug with New Applications. Int J Mol Sci. 2018; 19(10): 2863. doi: 10.3390/ijms19102863.Fahed G., Aoun L., Bou Zerdan M., Allam S., Bou Zerdan M., Bouferraa Y., Assi H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2): 786. doi: 10.3390/ijms23020786.Fahed G., Aoun L., Bou Zerdan M., Allam S., Bou Zerdan M., Bouferraa Y., Assi H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2): 786. doi: 10.3390/ijms23020786.Gluvic Z., Zaric B., Resanovic I., Obradovic M., Mitrovic A., Radak D., Isenovic E.R. Link between Metabolic Syndrome and Insulin Resistance. Curr Vasc Pharmacol. 2017; 15(1): 30–9. doi: 10.2174/1570161114666161007164510.Gluvic Z., Zaric B., Resanovic I., Obradovic M., Mitrovic A., Radak D., Isenovic E.R. Link between Metabolic Syndrome and Insulin Resistance. Curr Vasc Pharmacol. 2017; 15(1): 30–9. doi: 10.2174/1570161114666161007164510.McCracken E., Monaghan M., Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018; 36(1): 14–20. doi: 10.1016/j.clindermatol.2017.09.004.McCracken E., Monaghan M., Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018; 36(1): 14–20. doi: 10.1016/j.clindermatol.2017.09.004.Battelli M.G., Bortolotti M., Polito L., Bolognesi A. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase. Redox Biol. 2019; 21. doi: 10.1016/j.redox.2018.101070.Battelli M.G., Bortolotti M., Polito L., Bolognesi A. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase. Redox Biol. 2019; 21. doi: 10.1016/j.redox.2018.101070.Иванов В.В., Шахристова Е.В., Степовая Е.А., Носарева О.Л., Федорова Т.С., Рязанцева Н.В., Новицкий В.В. Окислительный стресс: влияние на секрецию инсулина, рецепцию гормона адипоцитами и липолиз в жировой ткани. Бюллетень сибирской медицины. 2014;13(3): 32–9. doi: 10.20538/1682-0363-2014-3-32-39.Ivanov V.V., Shakhristova Y.V., Stepovaya Y.A., Nosareva O.L., Fyodorova T.S., Ryazantseva N.V., Novitsky V.V. Oxidative stress: its role in insulin secretion, hormone reception by adipocytes and lipolysis in adipose tissue. Bulletin of Siberian Medicine. 2014; 13(3): 32–9. (in Russian). doi: 10.20538/1682-0363-2014-3-32-39.Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Chernyshova A.L., Kudryavtsev I.V., Tsydenova A.A. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors). Asia Pac J Clin Oncol. 2018; 14(3): 134–40. doi: 10.1111/ajco.12780.Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Chernyshova A.L., Kudryavtsev I.V., Tsydenova A.A. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors). Asia Pac J Clin Oncol. 2018; 14(3): 134–40. doi: 10.1111/ajco.12780.Zhang A.M.Y., Wellberg E.A., Kopp J.L., Johnson J.D. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021;45(3): 285–311. doi: 10.4093/dmj.2020.0250.Zhang A.M.Y., Wellberg E.A., Kopp J.L., Johnson J.D. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021;45(3): 285–311. doi: 10.4093/dmj.2020.0250.Chen M., Linstra R., van Vugt M.A.T.M. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2022; 1877(1). doi: 10.1016/j.bbcan.2021.188661.Chen M., Linstra R., van Vugt M.A.T.M. Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2022; 1877(1). doi: 10.1016/j.bbcan.2021.188661.Di Zazzo E., Polito R., Bartollino S., Nigro E., Porcile C., Bianco A., Daniele A., Moncharmont B. Adiponectin as Link Factor between Adipose Tissue and Cancer. Int J Mol Sci. 2019; 20(4): 839. doi: 10.3390/ijms20040839.Di Zazzo E., Polito R., Bartollino S., Nigro E., Porcile C., Bianco A., Daniele A., Moncharmont B. Adiponectin as Link Factor between Adipose Tissue and Cancer. Int J Mol Sci. 2019; 20(4): 839. doi: 10.3390/ijms20040839.Garikapati K.K., Ammu V.V.V.R.K., Krishnamurthy P.T., Chintamaneni P.K., Pindiprolu S.K.S.S. Type-II endometrial cancer: role of adipokines. Arch Gynecol Obstet. 2019; 300(2): 239–49. doi: 10.1007/s00404-019-05181-1.Garikapati K.K., Ammu V.V.V.R.K., Krishnamurthy P.T., Chintamaneni P.K., Pindiprolu S.K.S.S. Type-II endometrial cancer: role of adipokines. Arch Gynecol Obstet. 2019; 300(2): 239–49. doi: 10.1007/s00404-019-05181-1.Kahn C.R., Wang G., Lee K.Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129(10): 3990–4000. doi: 10.1172/JCI129187.Kahn C.R., Wang G., Lee K.Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019;129(10): 3990–4000. doi: 10.1172/JCI129187.Słabuszewska-Jóźwiak A., Lukaszuk A., Janicka-Kośnik M., Wdowiak A., Jakiel G. Role of Leptin and Adiponectin in Endometrial Cancer. Int J Mol Sci. 2022; 23(10): 5307. doi: 10.3390/ijms23105307.Słabuszewska-Jóźwiak A., Lukaszuk A., Janicka-Kośnik M., Wdowiak A., Jakiel G. Role of Leptin and Adiponectin in Endometrial Cancer. Int J Mol Sci. 2022; 23(10): 5307. doi: 10.3390/ijms23105307.Daley-Brown D., Oprea-Ilies G.M., Lee R., Pattillo R., Gonzalez- Perez R.R. Molecular cues on obesity signals, tumor markers and endometrial cancer. Horm Mol Biol Clin Investig. 2015; 21(1): 89–106. doi: 10.1515/hmbci-2014-0049.Daley-Brown D., Oprea-Ilies G.M., Lee R., Pattillo R., Gonzalez- Perez R.R. Molecular cues on obesity signals, tumor markers and endometrial cancer. Horm Mol Biol Clin Investig. 2015; 21(1): 89–106. doi: 10.1515/hmbci-2014-0049.Vavilova T.P., Pleten’A.P., Mikheev R.K. [Biological role of adipokines and their association with morbid conditions]. Vopr Pitan. 2017;86(2): 5–13. Russian. doi: 10.24411/0042-8833-2017-00028.Vavilova T.P., Pleten’A.P., Mikheev R.K. [Biological role of adipokines and their association with morbid conditions]. Vopr Pitan. 2017;86(2): 5–13. Russian. doi: 10.24411/0042-8833-2017-00028.Socol C.T., Chira A., Martinez-Sanchez M.A., Nuñez-Sanchez M.A., Maerescu C.M., Mierlita D., Rusu A.V., Ruiz-Alcaraz A.J., Trif M., Ramos-Molina B. Leptin Signaling in Obesity and Colorectal Cancer. Int J Mol Sci. 2022; 23(9): 4713. doi: 10.3390/ijms23094713.Socol C.T., Chira A., Martinez-Sanchez M.A., Nuñez-Sanchez M.A., Maerescu C.M., Mierlita D., Rusu A.V., Ruiz-Alcaraz A.J., Trif M., Ramos-Molina B. Leptin Signaling in Obesity and Colorectal Cancer. Int J Mol Sci. 2022; 23(9): 4713. doi: 10.3390/ijms23094713.Ilhan T.T., Kebapcilar A., Yilmaz S.A., Ilhan T., Kerimoglu O.S., Pekin A.T., Akyurek F., Unlu A., Celik C. Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis. Asian Pac J Cancer Prev. 2015; 16(11): 4503–8. doi: 10.7314/apjcp.2015.16.11.4503.Ilhan T.T., Kebapcilar A., Yilmaz S.A., Ilhan T., Kerimoglu O.S., Pekin A.T., Akyurek F., Unlu A., Celik C. Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis. Asian Pac J Cancer Prev. 2015; 16(11): 4503–8. doi: 10.7314/apjcp.2015.16.11.4503.Stępień S., Olczyk P., Gola J., Komosińska-Vassev K., Mielczarek-Palacz A. The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer. Cells. 2023; 12(8): 1118. doi: 10.3390/cells12081118.Stępień S., Olczyk P., Gola J., Komosińska-Vassev K., Mielczarek-Palacz A. The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer. Cells. 2023; 12(8): 1118. doi: 10.3390/cells12081118.Michalczyk K., Niklas N., Rychlicka M., Cymbaluk-Płoska A. The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics (Basel). 2021; 11(3): 494. doi: 10.3390/diagnostics11030494.Michalczyk K., Niklas N., Rychlicka M., Cymbaluk-Płoska A. The Influence of Biologically Active Substances Secreted by the Adipose Tissue on Endometrial Cancer. Diagnostics (Basel). 2021; 11(3): 494. doi: 10.3390/diagnostics11030494.VriensK.,ChristenS.,ParikS.,BroekaertD.,YoshinagaK.,TalebiA., Dehairs J., Escalona-Noguero C., Schmieder R., Cornfield T., Charlton C., Romero-Pérez L., Rossi M., Rinaldi G., Orth M.F., Boon R., Kerstens A., Kwan S.Y., Faubert B., Méndez-Lucas A., Kopitz C.C., Chen T., Fernandez-Garcia J., Duarte J.A.G., Schmitz A.A., Steigemann P., Najimi M., Hägebarth A., van Ginderachter J.A., Sokal E., Gotoh N., Wong K.K., Verfaillie C., Derua R., Munck S., Yuneva M., Beretta L., DeBerardinis R.J., Swinnen J.V., Hodson L., Cassiman D., Verslype C., Christian S., Grünewald S., Grünewald T.G.P., Fendt S.M. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566(7744): 403–6. doi: 10.1038/s41586-019-0904-1.VriensK.,ChristenS.,ParikS.,BroekaertD.,YoshinagaK.,TalebiA., Dehairs J., Escalona-Noguero C., Schmieder R., Cornfield T., Charlton C., Romero-Pérez L., Rossi M., Rinaldi G., Orth M.F., Boon R., Kerstens A., Kwan S.Y., Faubert B., Méndez-Lucas A., Kopitz C.C., Chen T., Fernandez-Garcia J., Duarte J.A.G., Schmitz A.A., Steigemann P., Najimi M., Hägebarth A., van Ginderachter J.A., Sokal E., Gotoh N., Wong K.K., Verfaillie C., Derua R., Munck S., Yuneva M., Beretta L., DeBerardinis R.J., Swinnen J.V., Hodson L., Cassiman D., Verslype C., Christian S., Grünewald S., Grünewald T.G.P., Fendt S.M. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature. 2019;566(7744): 403–6. doi: 10.1038/s41586-019-0904-1.Куликов В.А., Гребенников И.Н. Резолвины, протектины, марезины: новые медиаторы воспаления. Вестник Витебского государственного медицинского университета. 2012; 2: 25–30.Kulikov V.A., Grebennikov I.N. Resolvins, protectins, maresins: new mediators of inflammation. Bulletin of Vitebsk State Medical University. 2012; 2: 25–30. (in Russian).Panigrahy D., Gilligan M.M., Serhan C.N., Kashfi K. Resolution of inflammation:An organizing principle in biology and medicine. Pharmacol Ther. 2021; 227. doi: 10.1016/j.pharmthera.2021.107879.Panigrahy D., Gilligan M.M., Serhan C.N., Kashfi K. Resolution of inflammation:An organizing principle in biology and medicine. Pharmacol Ther. 2021; 227. doi: 10.1016/j.pharmthera.2021.107879.Tang S., Wan M., Huang W., Stanton R.C., Xu Y. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. Mediators Inflamm. 2018. doi: 10.1155/2018/2380319.Tang S., Wan M., Huang W., Stanton R.C., Xu Y. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. Mediators Inflamm. 2018. doi: 10.1155/2018/2380319.Kelly A.G., Panigrahy D. TargetingAngiogenesis via Resolution of Inflammation. Cold Spring Harb Perspect Med. 2023; 13(3). doi: 10.1101/cshperspect.a041172.Kelly A.G., Panigrahy D. TargetingAngiogenesis via Resolution of Inflammation. Cold Spring Harb Perspect Med. 2023; 13(3). doi: 10.1101/cshperspect.a041172.Liotti F., Marotta M., Melillo R.M., Prevete N. The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers (Basel). 2022; 14(14): 3333. doi: 10.3390/cancers14143333.Liotti F., Marotta M., Melillo R.M., Prevete N. The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers (Basel). 2022; 14(14): 3333. doi: 10.3390/cancers14143333.Dyall S.C., Balas L., Bazan N.G., Brenna J.T., Chiang N., da Costa Souza F., Dalli J., Durand T., Galano J.M., Lein P.J., Serhan C.N., Taha A.Y. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res. 2022; 86. doi: 10.1016/j.plipres.2022.101165.Dyall S.C., Balas L., Bazan N.G., Brenna J.T., Chiang N., da Costa Souza F., Dalli J., Durand T., Galano J.M., Lein P.J., Serhan C.N., Taha A.Y. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res. 2022; 86. doi: 10.1016/j.plipres.2022.101165.Doğan E.S.K., Doğan B., Fentoğlu Ö., Kırzıoğlu F.Y. The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J Periodontal Implant Sci. 2019; 49(2): 105–13. doi: 10.5051/jpis.2019.49.2.105.Doğan E.S.K., Doğan B., Fentoğlu Ö., Kırzıoğlu F.Y. The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J Periodontal Implant Sci. 2019; 49(2): 105–13. doi: 10.5051/jpis.2019.49.2.105.Denisenko Y.K., Kytikova O.Y., Novgorodtseva T.P., Antonyuk M.V., Gvozdenko T.A., Kantur T.A. Lipid-Induced Mechanisms of Metabolic Syndrome. J Obes. 2020. doi: 10.1155/2020/5762395.Denisenko Y.K., Kytikova O.Y., Novgorodtseva T.P., Antonyuk M.V., Gvozdenko T.A., Kantur T.A. Lipid-Induced Mechanisms of Metabolic Syndrome. J Obes. 2020. doi: 10.1155/2020/5762395.Börgeson E., Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol. 2012; 3: 318. doi: 10.3389/fimmu.2012.00318.Börgeson E., Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol. 2012; 3: 318. doi: 10.3389/fimmu.2012.00318.Kolawole O.R., Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022; 23(3): 1432. doi: 10.3390/ijms23031432.Kolawole O.R., Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. Int J Mol Sci. 2022; 23(3): 1432. doi: 10.3390/ijms23031432.Serhan C.N., Levy B.D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128(7):2657–69. doi: 10.1172/JCI97943.Serhan C.N., Levy B.D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128(7):2657–69. doi: 10.1172/JCI97943.Shan K., Feng N., Cui J., Wang S., Qu H., Fu G., Li J., Chen H., Wang X., Wang R., Qi Y., Gu Z., Chen Y.Q. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020; 24(14): 8045–56. doi: 10.1111/jcmm.15436.Shan K., Feng N., Cui J., Wang S., Qu H., Fu G., Li J., Chen H., Wang X., Wang R., Qi Y., Gu Z., Chen Y.Q. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020; 24(14): 8045–56. doi: 10.1111/jcmm.15436.Ji R.R. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Ann Rev Pharmacol Toxicol. 2023; 63: 273–93. doi: 10.1146/annurev-pharmtox-051921-084047.Ji R.R. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Ann Rev Pharmacol Toxicol. 2023; 63: 273–93. doi: 10.1146/annurev-pharmtox-051921-084047.Martínez-Fernández L., Laiglesia L.M., Huerta A.E., Martínez J.A., Moreno-Aliaga M.J. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins Other Lipid Mediat. 2015;121(Pt A): 24–41. doi: 10.1016/j.prostaglandins.2015.07.003.Martínez-Fernández L., Laiglesia L.M., Huerta A.E., Martínez J.A., Moreno-Aliaga M.J. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins Other Lipid Mediat. 2015;121(Pt A): 24–41. doi: 10.1016/j.prostaglandins.2015.07.003.Serhan C.N., Sulciner M.L. Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic? Cancer Metastasis Rev. 2023; 42(1): 13–7. doi: 10.1007/s10555-023-10091-5.Serhan C.N., Sulciner M.L. Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic? Cancer Metastasis Rev. 2023; 42(1): 13–7. doi: 10.1007/s10555-023-10091-5.Harwood J.L. Polyunsaturated Fatty Acids: Conversion to Lipid Mediators, Roles in Inflammatory Diseases and Dietary Sources. Int J Mol Sci. 2023; 24(10). doi: 10.3390/ijms24108838.Harwood J.L. Polyunsaturated Fatty Acids: Conversion to Lipid Mediators, Roles in Inflammatory Diseases and Dietary Sources. Int J Mol Sci. 2023; 24(10). doi: 10.3390/ijms24108838.Al-Shaer A.E., Buddenbaum N., Shaikh S.R. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochim BiophysActa Mol Cell Biol Lipids. 2021; 1866(7). doi: 10.1016/j.bbalip.2021.158936.Al-Shaer A.E., Buddenbaum N., Shaikh S.R. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochim BiophysActa Mol Cell Biol Lipids. 2021; 1866(7). doi: 10.1016/j.bbalip.2021.158936.Polus A., Zapala B., Razny U., Gielicz A., Kiec-Wilk B., Malczewska-Malec M., Sanak M., Childs C.E., Calder P.C., Dembinska-Kiec A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta. 2016; 1861(11): 1746–55. doi: 10.1016/j.bbalip.2016.08.005.Polus A., Zapala B., Razny U., Gielicz A., Kiec-Wilk B., Malczewska-Malec M., Sanak M., Childs C.E., Calder P.C., Dembinska-Kiec A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim Biophys Acta. 2016; 1861(11): 1746–55. doi: 10.1016/j.bbalip.2016.08.005.Dubé L., Spahis S., Lachaîne K., Lemieux A., Monhem H., Poulin S.M., Randoll C., Travaillaud E., Ould-Chikh N.E., Marcil V., Delvin E., Levy E. Specialized Pro-Resolving Mediators Derived from N-3 Polyunsaturated Fatty Acids: Role in Metabolic Syndrome and Related Complications. Antioxid Redox Signal. 2022; 37(1–3): 54–83. doi: 10.1089/ars.2021.0156.Dubé L., Spahis S., Lachaîne K., Lemieux A., Monhem H., Poulin S.M., Randoll C., Travaillaud E., Ould-Chikh N.E., Marcil V., Delvin E., Levy E. Specialized Pro-Resolving Mediators Derived from N-3 Polyunsaturated Fatty Acids: Role in Metabolic Syndrome and Related Complications. Antioxid Redox Signal. 2022; 37(1–3): 54–83. doi: 10.1089/ars.2021.0156.Sáinz N., Fernández-Galilea M., Costa AGV, Prieto-Hontoria P.L., Barraco G.M., Moreno-Aliaga M.J. n-3 polyunsaturated fatty acids regulate chemerin in cultured adipocytes: role of GPR120 and derived lipid mediators. Food Funct. 2020; 11(10): 9057–66. doi: 10.1039/d0fo01445a.Sáinz N., Fernández-Galilea M., Costa AGV, Prieto-Hontoria P.L., Barraco G.M., Moreno-Aliaga M.J. n-3 polyunsaturated fatty acids regulate chemerin in cultured adipocytes: role of GPR120 and derived lipid mediators. Food Funct. 2020; 11(10): 9057–66. doi: 10.1039/d0fo01445a.Martínez-Fernández L., González-Muniesa P., Laiglesia L.M., Sáinz N., Prieto-Hontoria P.L., Escoté X., Odriozola L., Corrales F.J., Arbones-Mainar J.M., Martínez J.A., Moreno-Aliaga M.J. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J. 2017; 31(5): 2135–45. doi: 10.1096/fj.201600859R.Martínez-Fernández L., González-Muniesa P., Laiglesia L.M., Sáinz N., Prieto-Hontoria P.L., Escoté X., Odriozola L., Corrales F.J., Arbones-Mainar J.M., Martínez J.A., Moreno-Aliaga M.J. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J. 2017; 31(5): 2135–45. doi: 10.1096/fj.201600859R.Юнусова Н.В., Кондакова И.В., Коломиец Л.А., Афанасьев С.Г., Чернышова А.Л., Шатохина О.В., Фролова А.Е., Zhiwei Zh., Wei W. Адипокины и их рецепторы у больных раком эндометрия и ободочной кишки: связь с инвазией и метастазированием. Вопросы онкологии. 2015; 61(4): 619–23.Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanasiev S.G., Chernyshova A.L., Shatohina O.V., Frolova A.E., Zhiwei Zh., Wei W. Serum adipokines and their receptors in endometrial and colon cancer patients: relationship with tumor invasion and metastasis. Problems in Oncology. 2015; 61(4): 619–23. (in Russian).Barden A., Shinde S., Tsai I.J., Croft K.D., Beilin L.J., Puddey I.B., Mori T.A. Effect of weight loss on neutrophil resolvins in the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2019; 148: 25–9. doi: 10.1016/j.plefa.2019.07.001.Barden A., Shinde S., Tsai I.J., Croft K.D., Beilin L.J., Puddey I.B., Mori T.A. Effect of weight loss on neutrophil resolvins in the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2019; 148: 25–9. doi: 10.1016/j.plefa.2019.07.001.Liu H., Zeng J., Huang W., Xu Q., Ye D., Sun R., Zhang D. Colorectal Cancer Is Associated with a Deficiency of Lipoxin A , an Endogenous Anti-inflammatory Mediator. J Cancer. 2019; 10(19): 4719–30. doi: 10.7150/jca.32456.Liu H., Zeng J., Huang W., Xu Q., Ye D., Sun R., Zhang D. Colorectal Cancer Is Associated with a Deficiency of Lipoxin A , an Endogenous Anti-inflammatory Mediator. J Cancer. 2019; 10(19): 4719–30. doi: 10.7150/jca.32456.Blogowski W., Dolegowska K., Deskur A., Dolegowska B., Starzynska T. Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report. Front Oncol. 2022; 11. doi: 10.3389/fonc.2021.757073.Blogowski W., Dolegowska K., Deskur A., Dolegowska B., Starzynska T. Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report. Front Oncol. 2022; 11. doi: 10.3389/fonc.2021.757073.Torres W., Pérez J.L., Díaz M.P., D’Marco L., Checa-Ros A., Carrasquero R., Angarita L., Gómez Y., Chacín M., Ramírez P., Villasmil N., Durán-Agüero S., Cano C., Bermúdez V. The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis. Int J Mol Sci. 2023; 24(16). doi: 10.3390/ijms241612623.Torres W., Pérez J.L., Díaz M.P., D’Marco L., Checa-Ros A., Carrasquero R., Angarita L., Gómez Y., Chacín M., Ramírez P., Villasmil N., Durán-Agüero S., Cano C., Bermúdez V. The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis. Int J Mol Sci. 2023; 24(16). doi: 10.3390/ijms241612623.Al-Zaubai N., Johnstone C.N., Leong M.M., Li J., Rizzacasa M., Stewart A.G. Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor. J Pharmacol Exp Ther. 2014; 351(1): 172–80. doi: 10.1124/jpet.114.214403.Al-Zaubai N., Johnstone C.N., Leong M.M., Li J., Rizzacasa M., Stewart A.G. Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor. J Pharmacol Exp Ther. 2014; 351(1): 172–80. doi: 10.1124/jpet.114.214403.

The authors declare that there are no conflicts of interest present.